Key points are not available for this paper at this time.
Background: An effective substitution for conventional administration routes is transdermal medication delivery. The use of transdermal treatments to treat arthritis has increased significantly in recent years. There is a pressing need to develop a new aceclofenac transdermal medication delivery method. Objective: The current study intends to stop aceclofenac from degrading in an aqueous environment in an effort to increase the drug's stability and effectiveness when used therapeutically to treat arthritis. The goal of the current research is to create non-aqueous, hydroxypropyl methyl cellulose-based transdermal patches for aceclofenac that will improve patient compliance, increase therapeutic efficacy, decrease gastrointestinal side effects, and prevent substantial first-pass metabolism. Method: By using a solvent evaporation approach, 18 different aceclofenac transdermal patch formulations, including HPMCK4M, HPMCK100M, and HPMCK15M, were created. The characterization of these prepared transdermal patches was done in vitro. Result: DSC thermograms concluded that there is no interaction between the API and excipients. The mass, weight variation, flatness, moisture content, moisture uptake, folding endurance, thickness, medication content, and swelling tests of these transdermal patches were all assessed. Good in-vitro physicochemical qualities could be seen in all of the improved formulations. The improved transdermal Patch (P13) was chosen for in-vivo investigations based on the findings. Conclusion: In order to increase the stability and effectiveness of aceclofenac during its therapeutic use for arthritis, it can therefore be reasonably inferred that it can be made into nonaqueous transdermal matrix type patches.
Bajaj et al. (Sun,) studied this question.